Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pancreatic Neoplasms
and you are
between 18 and 75
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Patients with locally advanced or metastatic pancreatic adenocarcinoma not eligible for infusional fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) (PPS 2 or hyperbilirubinemia, among other causes) will be treated with mFLOX regimen (fluorouracil bolus and oxaliplatin). The primary endpoint is to assess the objective response rate according to RECIST criteria (version 1.1) and the secondary endpoints are time until clinical or radiological progression, overall survival, toxicity profile.

Provided treatments

  • Drug: mFLOX
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02896803. The sponsor of the trial is Instituto do Cancer do Estado de São Paulo and it is looking for 37 volunteers for the current phase.
Official trial title:
A Phase II Trial of Bolus Fluorouracil and Oxaliplatin (mFLOX) as First-line Regimen for Patients With Unresectable or Metastatic Pancreatic Cancer Not Eligible for Infusional Fluorouracil, Irinotecan and Oxaliplatin